Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026

Haier Biomedical Accelerates Its Transformation into an Intelligent Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026 SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Haier Biomedical (SHA: 688139) showcased a portfolio of automated and digital solutions sp...

2026-09-01 22:48 2388

Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026

REJURAN COSMETICS Expands Across Canada with Nationwide Sephora Launch

Premium derma-cosmetic brand from PharmaResearch, the Korean pharmaceutical company behind the globally recognized REJURAN® skin booster available in more than 50 countries, will launch in Sephora Canada stores. SEOUL, South Korea, Sept. 1, 2026 /PRNewswire/ -- REJURAN COSMETICS, the premium der...

2026-09-01 20:47 1987

REJURAN COSMETICS Expands Across Canada with Nationwide Sephora Launch

Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development

NANJING, China, Sept. 1, 2026 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into an exclusive global licensing agreement with Roche for the development and commercialization of SIM0660, a tri-specific antibody targeting...

2026-09-01 20:28 2791

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Pa...

2026-09-01 19:30 1829

Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer

Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expec...

2026-09-01 19:15 2103

OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel

ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel. Dr. Chen brings nearly two decades of lega...

2026-09-01 19:00 2243

JIANGXI BIO Announced 2026 Interim Results

Overseas Contract Orders Reach Nearly RMB27.4 mn and R&D Translation Gains Momentum, with the AEPC Platform Reshaping the R&D Paradigm for Equine Polyclonal Antibody Interim Results Highlights Key Financial Indicators * Revenue amounted to RMB83.3 mn; gross profit amounted to RMB60.3 mn, ...

2026-09-01 14:44 5870

JIANGXI BIO Announced 2026 Interim Results

Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering

Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kaz...

2026-09-01 07:23 4959

Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia

The next generation in skin resurfacing technology is available to Australian health care practitioners beginning 1 September 2026 LAVAL, QC, Sept. 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics busines...

2026-09-01 06:00 2330

Convergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation Diseases

SUZHOU, China, Aug. 31, 2026 /PRNewswire/ -- Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $15 million Seed+ financing round. This round was led by MPCi, with part...

2026-08-31 21:00 2403

CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient...

2026-08-31 20:38 4316

T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors

MT027 has previously been granted FDA Orphan Drug Designation and has entered Phase II clinical development in recurrent glioblastoma BEIJING, Aug. 31, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") today announced that its investigational allogeneic CAR-T cell therapy MT027 ha...

2026-08-31 20:00 932

Samsung Biologics publishes prospectus for PolyPeptide public tender offer

* Direct subsidiary Samsung Peptide AG acting as formal offeror of the public tender offer * Publication of offer prospectus follows pre-announcement on July 20, 2026 * Largest individual shareholder committed to tender all of its PolyPeptide shares into offer * Main offer period expected ...

2026-08-31 13:00 1588

SIBIONICS Showcases GS3 in Melbourne, Advancing More Efficient, AI-Powered Glucose Monitoring

MELBOURNE, Australia, Aug. 31, 2026 /PRNewswire/ -- SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from 18–21 August. Through Booth #1, a scientific symposium and on-site interviews with...

2026-08-31 12:17 1100

Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore

* Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant and have received at lea...

2026-08-31 09:00 2190

WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion

SHANGHAI, Aug. 30, 2026 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 interim cash dividend. Building on its inaugural interim d...

2026-08-31 08:00 1881

Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management

- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. - Global Phase III clinical program to investigate efficacy and safety of three maintenance doses (20 mg, 40 mg, and 60 mg) over 72...

2026-08-30 18:15 2558

LifeTech Scientific Corporation Announces 2026 Interim Results

HONG KONG, Aug. 28, 2026 /PRNewswire/ -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral ...

2026-08-29 00:23 5233

Clicklinks | Sanyou Bio Launches Clicklinks, an AI-Driven Innovation Hub for Original Drug Discovery

SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Sanyou Bio"), today announced the official launch of Clicklinks, an AI-STAL and SAI-DA powered collaborative network designed to support original drug discovery and preclinical development. P...

2026-08-28 22:30 3045

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers

TSY-110 is positioned to become the first biosimilar alternative to Roche's Kadcyla® (ado-trastuzumab emtansine) in major regulated markets. TAIPEI, Aug. 28, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced the submission of a Clinical Trial Application (CTA) to E...

2026-08-28 20:03 1843

1 2 345 6 7 ... 347